Search

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.28

Max

0.3

Põhinäitajad

By Trading Economics

Sissetulek

2.6M

-5.5M

Müük

3M

38M

Aktsiakasum

-0.03

Kasumimarginaal

-14.573

Töötajad

128

EBITDA

2.1M

-5.5M

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-46M

51M

Eelmine avamishind

0.28

Eelmine sulgemishind

0.28

Uudiste sentiment

By Acuity

43%

57%

92 / 339 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. sept 2026, 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

25. sept 2026, 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

25. sept 2026, 23:35 UTC

News

DICK'S Sporting Goods faces two class action lawsuits alleging misleading financial statements, contributing to a modest decline in after-market trading.

25. sept 2026, 23:15 UTC

News

Skyworks Solutions Inc. has extended the expiration date for Qorvo's senior notes exchange offers to October 2, 2026, with shares modestly higher in after-market trading.

25. sept 2026, 23:05 UTC

News

PepsiCo plans to raise prices on select chips and sodas by late 2026 or early 2027 due to inflation and rising commodity costs, with stock roughly flat in after-market trading.

25. sept 2026, 23:05 UTC

News

Vicor Corp raised its third-quarter revenue growth outlook to over 20%, doubling its previous forecast, following a new OEM licensing agreement. Shares advanced in after-market trading.

25. sept 2026, 23:05 UTC

News

Moody's affirmed BJ's Wholesale Club's Ba1 rating and revised its outlook to positive, contributing to the asset's modest rise in after-market hours.

25. sept 2026, 23:05 UTC

News

Coca-Cola Consolidated Inc appointed Rob Gehring to lead North American operations, effective December 1, as the stock trades lower in after-market hours.

25. sept 2026, 23:05 UTC

News

Synopsys Inc is higher in after-market trading following HSBC's new price target of $700, citing AI's potential to enhance revenue capabilities.

25. sept 2026, 23:05 UTC

Event
News

Merck & Co. has withdrawn its Biologics License Application for ifinatamab deruxtecan after the FDA indicated insufficient trial data, with shares trading lower in after-market hours.

25. sept 2026, 23:05 UTC

News

Monster Beverage shares are modestly lower in after-market trading following CEO Rob Gehring's resignation announcement effective November 30, 2026.

25. sept 2026, 23:05 UTC

News

McDonald's Corp plans an $8.5 billion menu overhaul to introduce healthier options, with shares edging higher in after-market trading.

25. sept 2026, 23:01 UTC

News

Kodiak Sciences Inc. shares rose in after-market trading as the company announced topline results from its DAYBREAK Phase 3 study will be released on September 28, 2026.

25. sept 2026, 23:01 UTC

News

Chevron Corp's shares rose in after-market trading as the company accelerates plans to export gas from Cyprus's Aphrodite field through Egypt's LNG facilities.

25. sept 2026, 23:01 UTC

News

Marathon Petroleum's stock is higher in after-market hours as the White House reviews a potential diesel export ban that could impact earnings.

25. sept 2026, 23:01 UTC

News

PayPal shares rose in after-market hours amid speculation of a potential all-stock takeover and Deutsche Bank's price target increase to $55 from $50.

25. sept 2026, 22:50 UTC

News

S&P Global Ratings downgraded Cable One's credit rating to 'B+' amid increased competition, but the stock has advanced in after-market trading following five consecutive lower sessions.

25. sept 2026, 22:45 UTC

News

Viatris Inc is seeing a modest increase in after-market trading after filing a lawsuit against Novo Nordisk over its planned generic Wegovy.

25. sept 2026, 22:15 UTC

News

Fox Factory Holding Corp. completed the $225 million sale of Marucci Sports, reducing leverage and interest expenses, leading to higher shares in after-market hours.

25. sept 2026, 22:01 UTC

News

S&P Global Ratings upgraded Rithm Capital Corp's credit rating to 'B+' as the firm diversifies revenue, with assets under management rising to $61 billion.

25. sept 2026, 21:02 UTC

News

The New York Times Company declared a quarterly dividend of $0.23 per share, while the stock traded modestly lower in after-market hours.

25. sept 2026, 21:01 UTC

News

Best Buy Co., Inc. plans to sell debt securities, contributing to a modest decline in after-market trading, with shares lower since Friday's close.

25. sept 2026, 20:08 UTC

Social Media
News

Moderna Inc's stock advanced following CEO Stéphane Bancel's comments on focusing on cancer vaccines and recent positive trial results for its melanoma vaccine.

25. sept 2026, 20:08 UTC

Social Media
News

Apple shares are advancing as Bernstein maintains a Buy rating with a $370 price target, despite lowering EPS estimates for Q1 to $2.87.

25. sept 2026, 20:08 UTC

News

ON Semiconductor Corp shares are sharply higher, driven by the launch of its Embedded Power Platform and strengthened partnerships in automotive and AI sectors.

25. sept 2026, 20:08 UTC

News

C3.ai Inc shares declined modestly as options sentiment remained mixed, with a put/call ratio of 0.33 and implied volatility in the lowest 10% of observations.

25. sept 2026, 20:08 UTC

News

Snowflake Inc. shares are advancing as the company partners with CrowdStrike to integrate its AI-native Falcon platform into the Snowflake Marketplace.

25. sept 2026, 20:08 UTC

Correlated Moves
News

Box Inc shares fell as the resignation of Chief Accounting Officer Eli Berkovitch may have contributed to the stock's ongoing decline, marking six consecutive days lower.

25. sept 2026, 20:08 UTC

Social Media
News

Amazon.com Inc. saw moderately bullish options activity, with calls outpacing puts and a put/call ratio of 0.43, amid rising sentiment for October call options.

25. sept 2026, 20:08 UTC

News

Aflac shares fell today as Japan Post Holdings sold 12.2k shares, contributing to a price move slightly below Thursday's close.

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

92 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.